KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Share-based Compensation: 2018-2025

Historic Share-based Compensation for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to $125.0 million.

  • Moderna's Share-based Compensation rose 11.61% to $125.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $474.0 million, marking a year-over-year increase of 17.33%. This contributed to the annual value of $429.0 million for FY2024, which is 40.66% up from last year.
  • According to the latest figures from Q3 2025, Moderna's Share-based Compensation is $125.0 million, which was down 3.85% from $130.0 million recorded in Q2 2025.
  • Over the past 5 years, Moderna's Share-based Compensation peaked at $130.0 million during Q2 2025, and registered a low of $30.0 million during Q1 2021.
  • Over the past 3 years, Moderna's median Share-based Compensation value was $104.0 million (recorded in 2024), while the average stood at $100.4 million.
  • Data for Moderna's Share-based Compensation shows a peak YoY skyrocketed of 81.82% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Moderna's Share-based Compensation stood at $37.0 million in 2021, then surged by 67.57% to $62.0 million in 2022, then climbed by 27.42% to $79.0 million in 2023, then spiked by 31.65% to $104.0 million in 2024, then climbed by 11.61% to $125.0 million in 2025.
  • Its Share-based Compensation was $125.0 million in Q3 2025, compared to $130.0 million in Q2 2025 and $115.0 million in Q1 2025.